Why is AdaptHealth stock plummeting today?
AdaptHealth (AHCO) shares fell about 22% in pre-open after it reported Q2 2026 results. Analysts expected EPS of $0.15–$0.18 on revenue near $849M. The company has posted GAAP losses of $0.12 in Q1 2026 and $0.76 in Q4 2025. It also agreed to sell its Diabetes Health segment to Cardinal Health for $235M, with guidance to be addressed on the earnings call.
How this was made
The 30-second read
Why it matters
The article links the outsized pre-market decline to profitability disappointment, potential full-year guidance revision, and added uncertainty from the Diabetes Health divestiture and its discontinued-operations accounting.
Market read
Traders are likely repricing AdaptHealth’s return-to-profitability timeline and the credibility of full-year guidance after the Diabetes Health sale reclassification.
What to watch
Investors may be focusing too narrowly on GAAP profitability timing versus cash flow trajectory and the operational impact of the Kaiser capitated contract labor-cost dynamics beyond Q1.
Background
AdaptHealth reported Q2 2026 results before the market open, following prior GAAP losses and a July 19 agreement to sell its Diabetes Health segment to Cardinal Health for $235 million.
Ticker impact
AdaptHealth shares fell 22.3% pre-open after Q2 2026 results disappointed on profitability and the Diabetes Health divestiture introduced discontinued-ops and guidance uncertainty.
Bearish near-term as investors reprice the path back to GAAP profitability and discount guidance clarity until management details the post-divestiture outlook.
The article cites a large pre-market drop tied to Q2 profitability disappointment, GAAP losses history, and potential downward full-year guidance, all of which typically pressure valuation and risk appetite for the name.
Market effects
Home health and hospice peers’ solid results raise the bar, increasing relative pressure on AdaptHealth’s recovery narrative.
No specific regional spillover described; move is framed as idiosyncratic.
No global macro or cross-border catalyst mentioned.
Counterpoint
The Diabetes Health divestiture could simplify the business and improve future margins, so the market may be over-discounting near-term GAAP optics from discontinued-ops reclassification.
Key entities
- companyAdaptHealth Corp
Subject of the article, with shares down 22.3% pre-open after Q2 2026 results and guidance uncertainty tied to profitability and the Diabetes Health divestiture.
- companyCardinal Health
Counterparty to AdaptHealth’s July 19 agreement to divest the Diabetes Health segment for $235 million in cash.
- financial_institutionBofA
Mentioned as saying a memory stock could double, but not directly tied to AdaptHealth’s fundamentals in the provided text.
